DaVita Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Los beneficios de DaVita han disminuido a una tasa media anual de -0.9%, mientras que en la industria Healthcare los beneficios crecieron en un 7.1% anualmente. Los ingresos han ido creciendo a una tasa media de 1% al año. La rentabilidad financiera de DaVita es de 34.9%, y sus márgenes netos son de 5.7%.

Información clave

-1.0%

Tasa de crecimiento de los beneficios

10.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	8.5%
Tasa de crecimiento de los ingresos	1.2%
Rentabilidad financiera	41.4%
Margen neto	6.6%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

DaVita Stock Is A Hold As It Expands In Latin America

Mar 18

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

Mar 13

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Mar 04

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16

DaVita could benefit from legislation that would return dialysis protection to Medicare

Aug 16

We Think DaVita (NYSE:DVA) Is Taking Some Risk With Its Debt

Aug 14

DaVita stock dips as peer Fresenius outlook weighed down by labor cost, inflation

Jul 28

DaVita: Valuation Turning Attractive

Jul 16

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Jul 13

Here's Why I Think DaVita (NYSE:DVA) Is An Interesting Stock

May 15

DaVita Offers Stability During Market Volatility

May 12

Here's Why DaVita (NYSE:DVA) Has A Meaningful Debt Burden

Apr 29

Is It Time To Consider Buying DaVita Inc. (NYSE:DVA)?

Apr 14

DaVita's Wide Moat Is Undervalued

Feb 11

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero DaVita. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:DVA Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Mar 24	12,338	816	1,505
31 Dec 23	12,140	692	1,474
30 Sep 23	11,911	596	1,424
30 Jun 23	11,739	454	1,441
31 Mar 23	11,665	500	1,392
31 Dec 22	11,610	547	1,355
30 Sep 22	11,637	680	1,298
30 Jun 22	11,627	834	1,226
31 Mar 22	11,616	903	1,209
31 Dec 21	11,619	978	1,195
30 Sep 21	11,580	984	1,177
30 Jun 21	11,566	883	1,247
31 Mar 21	11,529	791	1,230
31 Dec 20	11,551	783	1,248
30 Sep 20	11,544	832	1,186
30 Jun 20	11,524	824	1,122
31 Mar 20	11,487	816	1,116
31 Dec 19	11,388	705	1,103
30 Sep 19	11,311	623	1,093
30 Jun 19	11,253	548	1,131
31 Mar 19	11,300	551	1,120
31 Dec 18	11,412	616	1,135
30 Sep 18	11,378	617	1,120
30 Jun 18	11,299	698	1,057
31 Mar 18	11,110	652	1,056
31 Dec 17	10,884	909	1,052
30 Sep 17	7,773	1,065	707
30 Jun 17	8,732	1,480	825
31 Mar 17	9,747	1,382	949
31 Dec 16	10,696	1,038	1,057
30 Sep 16	14,550	716	1,573
30 Jun 16	14,347	361	1,536
31 Mar 16	14,065	478	1,497
31 Dec 15	9,973	323	1,031
30 Sep 15	13,565	484	1,399
30 Jun 15	13,290	452	1,369
31 Mar 15	13,027	429	1,319
31 Dec 14	12,781	723	1,262
30 Sep 14	12,519	727	1,224
30 Jun 14	12,270	680	1,207
31 Mar 14	11,971	787	1,176
31 Dec 13	11,759	620	1,176
30 Sep 13	11,174	564	1,119
30 Jun 13	10,121	572	1,009

Ingresos de calidad: DVA tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (5.7%) de DVA son superiores a los del año pasado (4.7%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de DVA han disminuido en un 0.9% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de DVA en el último año (26.4%) supera su media de 5 años (-0.9% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de DVA en el último año (26.4%) superó al de la industria Healthcare 7.3%.

Rentabilidad financiera

Alta ROE: Aunque la rentabilidad financiera (41.44%) de DVA es excepcional, esta métrica está sesgada debido a su alto nivel de deuda.

DaVita Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

DaVita Inc. to Report Q1, 2024 Results on May 02, 2024

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

Recent updates

Price target increased by 9.0% to US$140

High number of new directors

DaVita Inc., Annual General Meeting, Jun 06, 2024

DaVita Inc. to Report Q1, 2024 Results on May 02, 2024

Davita Announces Dennis Pullin to Its Board of Directors

DaVita Stock Is A Hold As It Expands In Latin America

Chief Operating Officer of Kidney Care exercised options and sold US$3.0m worth of stock

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

CEO & Executive Director exercised options and sold US$36m worth of stock

Price target increased by 7.4% to US$131

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Chief Compliance Officer recently sold US$3.0m worth of stock

Chief Compliance Officer notifies of intention to sell stock

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Price target increased by 14% to US$120

Is DaVita (NYSE:DVA) Using Too Much Debt?

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

DaVita: Assessing After The Rally

DaVita Inc.'s (NYSE:DVA) Subdued P/E Might Signal An Opportunity

CEO & Executive Director exercised options and sold US$16m worth of stock

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 13%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet

DaVita: Simple And Compelling After Sell-Off

Returns On Capital Signal Difficult Times Ahead For DaVita (NYSE:DVA)

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 19%

DaVita: Continued Economic Hurdles, Market Expectations May Be Correct

Chief Legal & Public Affairs Officer notifies of intention to sell stock

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Price target increased by 7.3% to US$113

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Takes On Some Risk With Its Use Of Debt

DaVita Inc. Announces Management Changes

DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold

Returns At DaVita (NYSE:DVA) Appear To Be Weighed Down

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

DaVita Inc. (NYSE:DVA) Shares Could Be 41% Below Their Intrinsic Value Estimate

Chief Legal & Public Affairs Officer recently sold US$1.0m worth of stock

CEO & Executive Director notifies of intention to sell stock

Price target increased by 8.1% to US$96.27

Price target increased by 8.3% to US$94.38

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

What Is DaVita Inc.'s (NYSE:DVA) Share Price Doing?

Price target increased by 8.6% to US$88.80

These 4 Measures Indicate That DaVita (NYSE:DVA) Is Using Debt Extensively

Investors Met With Slowing Returns on Capital At DaVita (NYSE:DVA)

Director recently sold US$108k worth of stock

Are Investors Undervaluing DaVita Inc. (NYSE:DVA) By 40%?

Director exercised options and sold US$106k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 7.0% to US$86.50

DaVita HealthCare Partners Q4 2022 Earnings Preview

Moon Capital - DaVita: A Recession-Resistant Cash Generating Machine

DaVita Inc. to Report Q4, 2022 Results on Feb 22, 2023

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

Is DaVita (NYSE:DVA) A Risky Investment?

DaVita: Shares Still Appear Cheap After Outlook Cut, Technicals Suggest Caution

Consensus EPS estimates fall by 21%

Independent Director recently bought US$356k worth of stock

Price target decreased to US$83.57

Third quarter 2022 earnings: EPS misses analyst expectations

DaVita Q3 2022 Earnings Preview

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

DaVita Inc. to Report Q3, 2022 Results on Oct 28, 2022

DaVita: Solid Valuation And Cash Flow, Price Recovering After SCOTUS Ruling

DaVita Inc. Appoints Adam H. Schechter to Board of Directors

Desglose de ingresos y gastos
Beta